AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04249531
Drug: Amikacin Injectable Product
RxNorm normalized name: amikacin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient wil receive one dose of 400 mg amikacine intravenously in week 1
Trial: NCT01554683
Drug: Low/High/Placebo Dose Keppra (Levetiracetam)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose (2.5 mg/kg) High Dose (7.5 mg/kg) Placebo (Saline)
Trial: NCT04700449
Drug: Double-Blind 0.2mg CBP-307
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg capsule oral administration
Trial: NCT04700449
Drug: Double-Blind Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule oral administration
Trial: NCT04700449
Drug: Double-Blind 0.1mg CBP-307
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg capsule oral administration
Trial: NCT01238848
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cc nebulized hypertonic saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
Trial: NCT01238848
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cc nebulized normal saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
Trial: NCT04826510
Drug: Lithium carbonate + perospirone hydrochloride
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The stable blood lithium concentration was 0.5-1.2 mmol / L, and the dose of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
Trial: NCT03643666
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: before closure of the laparoscopic entering sites the patients received instillation of 40 ml normal saline into the peritoneum
Trial: NCT01751152
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
Trial: NCT00655642
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume matched isotonic sodium chloride solution dose administered over 2 minutes through a peripheral intravenous catheter
Trial: NCT00753571
Drug: Cistanche Total Glycosides
RxNorm normalized name: anthraquinone glycoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Cistanche Total Glycosides Cistanche Total Glycosides ,1.8g/day(6 capsules) po Qd\*9months Arms: 1 Drug: blank capsules 6 capsules po Qd\*9months~Arms: 2
Trial: NCT00519337
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid, 2 g p.o. the night before surgery followed by 500mg B.I.D. for 4 post-operative days
Trial: NCT00782509
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler
Trial: NCT03012477
Drug: AZD1775
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wee1 tyrosine kinase inhibitor
Trial: NCT04278469
Drug: Chemotherapy Drugs, Cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical high and genomic low Hormone Receptor-positive early breast cancer patients with or without adjuvant chemotherapy
Trial: NCT03286582
Drug: AC-203 1% Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC-203 1% ointment BID (twice daily)
Trial: NCT01653665
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the randomised controlled trial may receive this placebo as a single daily subcutaneous injection. The volume will match that of the active drug.
Trial: NCT00769210
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg tablet
Trial: NCT00153907
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taken twice a day on days 1-14 until disease progression or unacceptable side effects occur.
Trial: NCT00395226
Drug: zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: zinc sulfate 220 mg bis for 90 days
Trial: NCT02624843
Drug: Ulesfia (benzyl alcohol lotion) 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White topical lotion
Trial: NCT02624843
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White topical lotion
Trial: NCT01747850
Drug: Placebo spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study subjects will gradually increase the maximal allowed dose of Placebo starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The Placebo treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Placebo Spray that will be decreased by 50%). Then exposure to Placebo will be stopped (so there will be a total of 12 weeks Placebo treatment exposure).
Trial: NCT01197261
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets/ day
Trial: NCT02270736
Drug: NT 201 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT 201 placebo matching injection.
Trial: NCT02270736
Drug: NT 201
RxNorm normalized name: Fluarix Quadrivalent 2013-2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT 201 injection.
Trial: NCT03789214
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Sleep Medication
Trial: NCT02737397
Drug: JMI-001 (SJP-304 and SJP-223)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02737397
Drug: SJP-304
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02737397
Drug: SJP-223
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02737397
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04887844
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
Trial: NCT02132247
Drug: Diclofenac hydroxyethylpyrrolidine
RxNorm normalized name: diclofenac hydroxyethylpyrrolidine 1.292 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03230851
Drug: aspirin 100mg/d therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg aspirin for at least 5 days followed by aspirin 100mg/d
Trial: NCT03230851
Drug: aspirin 100mg/2d therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg aspirin for at least 5 days followed by aspirin 100mg/2d
Trial: NCT03230851
Drug: aspirin 100mg/3d therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg aspirin for at least 5 days followed by aspirin 100mg/3d
Trial: NCT03230851
Drug: aspirin 75mg/d therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg aspirin for at least 5 days followed by aspirin 75mg/d
Trial: NCT03230851
Drug: aspirin 50mg/d therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg aspirin for at least 5 days followed by aspirin 50mg/d
Trial: NCT00359086
Drug: MGCD0103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGCD0103 given orally three times per week
Trial: NCT02422823
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000552
Drug: thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01451853
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules, 0 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
Trial: NCT03573297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules, oral administration, once daily
Trial: NCT01232595
Drug: LFF571
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00242320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01517620
Drug: Total Glucosides Paeony Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Glucosides Paeony Capsules, oral, 0.3 gram per capsule, 3 capsules tid, 24 weeks
Trial: NCT04208997
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation of amiodarone or sotalol.
Trial: NCT01708161
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BYL719 is a small molecule inhibiting PI3-Kinase.
Trial: NCT05629949
Drug: QL1701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
Trial: NCT03106870
Drug: Insulin Mixtard
RxNorm normalized name: insulin isophane, human / insulin, regular, human Injectable Suspension [Human Mixtard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin dose:~* 0.7 IU/Kg (at the second trimester of pregnancy).~* 0.8 IU/Kg (at the third trimester of pregnancy). Insulin dose was raised at a rate of 1 IU for every 10 mg/dl higher than the target blood glucose concentration.
Trial: NCT01644500
Drug: Placebo as Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for glimepiride is administered orally as one to three capsules daily.
Trial: NCT01642979
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoids 0.5-1mg/kg every day(prednisone)
Trial: NCT01644500
Drug: Placebo as SC Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for dulaglutide is administered as one SC injection.
Trial: NCT00796900
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
Trial: NCT03445195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching 1g IV solution.
Trial: NCT01617577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle (D5W or 5% dextrose solution) is administered subcutaneously daily for 5 days
Trial: NCT00851487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo was similar in colour, consistency and volume as oral amoxicillin
Trial: NCT03923036
Drug: Antineoplastic Agents
RxNorm normalized name: ANTINEOPLASTIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure measurement to any anticancer drug in its therapeutic use for the metastatic colorectal cancer with its posology and duration (the list provided is non-limitative). Exposure to anticancer drugs for another indication than the colorectal cancer will also be collected.
Trial: NCT03405207
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical as active drug providing by pharmaceutical company unless it is placebo
Trial: NCT01138683
Drug: diuretics
RxNorm normalized name: DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide continuous infusion to reach a prescribed negative fluid balance: dose adjustment according to the diuretic response.
Trial: NCT04005768
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
Trial: NCT02860052
Drug: SB208 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply once daily to one or both feet for 14 days
Trial: NCT02860052
Drug: SB208 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply once daily to one or both feet for 14 days
Trial: NCT02860052
Drug: SB208 16%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply once daily to one or both feet for 14 days
Trial: NCT02860052
Drug: Vehicle Gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply once daily to one or both feet for 14 days
Trial: NCT03069989
Drug: GSK3008348
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal.
Trial: NCT03069989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20mm stopper and aluminium seal.
Trial: NCT03069989
Drug: [18F]-FBA-A20FMDV2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radio-labeled peptide ligand for PET scan. Available as intravenous (IV) infusion, 20 mL.
Trial: NCT02154074
Drug: general anesthesia induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg
Trial: NCT02154074
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the same volume of saline + Isoflurane during operation
Trial: NCT01172522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00335413
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003052
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03122002
Drug: Drug Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For this observation research, anti platelet drugs, statins and ect. would be used as clinical guidelines as usal, and statical ananysis of the relationship between these drugs and the final outcomes
Trial: NCT03146377
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
Trial: NCT04203498
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 microliters (μL) containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
Trial: NCT01474083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-matched placebo. Oral administration.
Trial: NCT04203797
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-filled syringe administered by subcutaneous (SC)
Trial: NCT03882112
Drug: HIP1601 40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dosing of HIP1601 40mg, orally
Trial: NCT00120900
Drug: GW406381
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01235689
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants with normal thiopurine methyltransferase (TPMT) enzyme activity could receive oral azathioprine 2.5 mg/kg/day. In participants with intermediate TPMT enzyme activity azathioprine was initiated at a dose of 1.25 mg/kg/day. The dose of azathioprine was adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine.
Trial: NCT03309618
Drug: low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03309618
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02305316
Drug: BIA 9-1067 non-micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02305316
Drug: BIA 9-1067 micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05322486
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with or without biological drugs.
Trial: NCT03231475
Drug: SPH1188-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: qd.po
Trial: NCT00662025
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
Trial: NCT02551497
Drug: CNV1014802
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00528242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00379457
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00379457
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00930865
Drug: Bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 1 mg, Single Dose, 7 Days
Trial: NCT00670956
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLACEBO: IM x 2 doses 24 hours apart
Trial: NCT01601509
Drug: Nasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described \[7\], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
Trial: NCT00454636
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle
Trial: NCT00454636
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 625 mg/m2, oral, twice daily per 3-week cycle
Trial: NCT00454636
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m2, oral, twice daily for 2 weeks
Trial: NCT00197951
Drug: Treatment of psychiatric symptoms associated to alcoholism
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00963157
Drug: AS03
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03 adjuvant administered with 3.75, 7.5, or 15 mcg inactivated H1N1 vaccine.
Trial: NCT01328275
Drug: standard regimens according to the Thai Ministry of Public Health national guidelines
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
Trial: NCT00996671
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to be used as comparator for GSK2256098
Trial: NCT04514393
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous methotrexate at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 of all cycles，for up to 4 cycles.
Trial: NCT00510510
Drug: NVA237 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder inhalation once a day for up to 28 days
Trial: NCT00510510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to NVA237 dry powder inhalation once a day for up to 28 days